Blog / Events / Videos

18 Dec 2020

Watch the first COG-UK Showcase Event – 16th Dec 2020

COG-UK

Thank you to all the speakers, chairs, attendees and organisers of the very first COG-UK Showcase Event: SARS-CoV-2 sequencing to inform clinical care, public health interventions and policy decisions.

The afternoon was filled with an array of thought-provoking talks, covering stimulating topics and research areas related to SARS-CoV-2 genome sequencing and what it has taught us to date about the ongoing COVID-19 pandemic.

The event featured an exceptional line-up of speakers, covering the focal themes of mutations and their implications for transmission, disease severity, therapeutics and vaccines; genomic-informed evidence on transmission in specific environments; and an overview of SARS-CoV-2 lineage introduction and transmission.

If you missed the live event, you can watch the full recording here.

SARS-CoV-2 sequencing to inform clinical care, public health interventions and policy decisions

COG-UK Showcase event, 16th of December 2020

 

Draft Programme:

14.00

Welcome from the Director of COG-UK  –  Sharon Peacock

14.05

Opening remarks, Sir Patrick Vallance, CSA, England

 

Session 1 – Overview of the Four Nations Experience: lineage introduction and transmission

Chair –  Rob Orford

14.10 – Scotland – Matt Holden

14.20 – Wales – Tom Connor

14.30 – Northern Ireland – Derek Fairley

14.40 – England – Meera Chand

14.50 – Summary and Implications for policy and practice – Deenan Pilay

 

15.00 – break

 

Session 2 – Overview of Genomic-Informed Evidence on Transmission in Specific Environments

Chair – David Crossman

15.10 – Hospitals – Estee Torok

15.20 – Care homes – Dinesh Aggarwal

15.30 – Universities – Ben Warne

15.40 – Sentinel surveillance using pillar 2 samples – Jeff Barratt

15.50 – The HOCI study – Judy Breuer

16.00 – Summary and implications for policy and practice – Gordon Dougan

 

16.10 – break

 

Session 3 – SARS-CoV-2 Mutations – Implications for Transmission, Disease Severity, Therapeutics and Vaccines

Chair: Ian Young

16.20 – Overview: prevalence, tracking and importance – David Robertson

16.30 – Mutations and transmissibility – Erik Volz

16.40 – Mutations and clinical consequences – Emma Thomson

16.50 – SARS-CoV-2 mutational escape from therapeutic convalescent plasma – Ravi Gupta

17.00 – Coordination of mutation data for public health use – Alessandro Carabelli

 

17.10 – Closing remarks from the Director of COG-UK, Sharon Peacock

 

 

COVID-19 Genomics UK (COG-UK)

The current COVID-19 pandemic, caused by the SARS-CoV-2, represents a major threat to health. The COVID-19 Genomics UK (COG-UK) consortium has been created to deliver large-scale and rapid whole-genome virus sequencing to local NHS centres and the UK government.

Led by Professor Sharon Peacock of the University of Cambridge, COG-UK is made up of an innovative partnership of NHS organisations, the four Public Health Agencies of the UK, the Wellcome Sanger Institute and twelve academic partners providing sequencing and analysis capacity. A full list of collaborators can be found here: https://www.cogconsortium.uk/about/. Professor Peacock is also on a part-time secondment to PHE as Director of Science, where she focuses on the development of pathogen sequencing through COG-UK.

COG-UK was established in March 2020 supported by £20 million funding from the UK Department of Health and Social Care (DHSC), UK Research and Innovation (UKRI) and the Wellcome Sanger Institute, administered by UK Research and Innovation. For more information, visit: https://www.cogconsortium.uk


COVID-19 Genomics UK (COG-UK)

The COVID-19 Genomics UK (COG-UK) consortium works in partnership to harness the power of SARS-CoV-2 genomics in the fight against COVID-19.

Led by Professor Sharon Peacock of the University of Cambridge, COG-UK is made up of an innovative collaboration of NHS organisations, the four public health agencies of the UK, the Wellcome Sanger Institute and sixteen academic partners. A full list of collaborators can be found here.

The COVID-19 pandemic, caused by SARS-CoV-2, represents a major threat to health. The COG-UK consortium was formed in March 2020 to deliver SARS-CoV-2 genome sequencing and analysis to inform public health policy and to support the establishment of a national pathogen sequencing service, with sequence data now predominantly generated by the Wellcome Sanger Institute and the Public Health Agencies.

SARS-CoV-2 genome sequencing and analysis plays a key role in the COVID-19 public health response by enabling the identification, tracking and analysis of variants of concern, and by informing the design of vaccines and therapeutics. COG-UK works collaboratively to deliver world-class research on pathogen sequencing and analysis, maximise the value of genomic data by ensuring fair access and data linkage, and provide a training programme to enable equity in global sequencing.